Celyad Oncology SA
CLYYF
$0.25
-$0.10-28.57%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 276.97% | 272.33% | -27.30% | -17.03% | 41.53% |
| Total Depreciation and Amortization | -173.10% | -171.12% | -6.01% | -13.68% | -58.69% |
| Total Amortization of Deferred Charges | -24.28% | -26.12% | -- | -- | 18.59% |
| Total Other Non-Cash Items | -4,192.85% | -4,080.61% | 361.90% | 324.53% | -149.04% |
| Change in Net Operating Assets | -1,241.38% | -1,205.07% | 150.00% | 145.82% | 95.83% |
| Cash from Operations | -38.99% | -35.34% | -21.94% | -12.11% | 58.94% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | 21,777.50% | 21,336.59% | -- | -- | -42.86% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Investing | 21,777.50% | 21,336.59% | -- | -- | 102.66% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 36.90% | 36.90% | 12.05% | 12.05% | -58.49% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -30.72% | -30.72% | -102.79% | -102.79% | 4,360.00% |
| Cash from Financing | 106.76% | 101.40% | -106.60% | -106.06% | -91.54% |
| Foreign Exchange rate Adjustments | 266.67% | 259.09% | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | 20.00% | 0.00% | -20.00% | 0.00% | -- |
| Net Change in Cash | 149.41% | 148.11% | -363.94% | -326.48% | -199.06% |